Create

Sign in to ReadmeX

or

How we handle your data: Privacy Policy

ReadmeX

Your AI reading companion

What would you like to catch up on?

Pick a briefing, or ask your own question.

Your community and people briefings stay personal to you.

DP Technology

AI overview

Sign in and the AI will write an overview from our coverage.

Headlines · 3

  1. Moonshot AI redirects Kimi toward science

    The Decoder reports that Moonshot AI is redirecting its Kimi language models from coding toward biology, chemistry, and pharmaceutical research because the company sees diminishing returns in coding. Moonshot AI international director Giacomo Ficari said at the Web Summit in Lisbon that science demands smarter models than law, finance, or code. DP Technology is integrating Kimi K3.1 Pro into its research assistant BioMaster. In one partner test, the system analyzed gene data from 3,696 mouse pancreatic cells and flagged 100 candidate genes in 90 minutes, compared with an estimated four hours of human work. The report also notes that leading models produced verifiable proofs on TCSExam but solved no open conjectures alone. A June Citi survey of 50 US research leaders found that 24% expected AI to noticeably improve drug-development success rates.

    The Decoder · 🔥 0
  2. AI pharma's pivotal test: Rentosertib Phase III readout due 2029

    The article reports that Anew Labs, an AI drug-discovery company spun out of ByteDance, raised a $290 million first round at a $1.5 billion valuation, and that Anthropic has reportedly built a wet lab in the San Francisco Bay Area where Claude drives robots to run real biological experiments. It divides the AI pharma chain into three groups — upstream AI technology firms such as Insilico Medicine, midstream CRO/CDMO wet-lab service providers such as GenScript and Twist Bioscience, and downstream pharma companies including Fosun Pharma and Hengrui Pharmaceuticals — and cites brokerage estimates that AI can cut drug-discovery timelines by 70%-90% and total R&D cost by roughly 50%. The decisive test is Insilico's lead asset Rentosertib, whose Phase IIa showed a 98.4 mL mean lung-capacity gain at 60 mg versus a 20.3 mL decline in controls; its China Phase III began in July 2026 with 320 planned participants and top-line data expected in 2029.

    36氪 人工智能 · 🔥 0
  3. Weinan E: AI for Science's second half is rebuilding the research system

    Speaking at PAIR Conference 2026 in Shanghai, Chinese Academy of Sciences academician Weinan E argued that AI for Science has two layers: as research becomes “industrialized,” it needs new infrastructure — compute, models/algorithms/software, databases and knowledge bases, and automated labs (China has pushed this “platform research” approach since 2022) — while the “second half” is change in the research system itself. He said theory and computation matter alongside automated labs and literature mining: DPA-4 now covers organic molecules, catalysis and complex interfaces, but is still two to three orders of magnitude from materials and process design, and a “science foundation model” built by fine-tuning open general models may be a false premise if the underlying base model is weak. He also called for breaking three boundaries: theory/experiment, between disciplines, and research/industry.

    MIT科技评论中文 · 🔥 0

Experience and discussion from the community

Share my DP Technology experienceAsk about DP Technology

Nobody has shared their experience with DP Technology yet.